Elkfork Partners LLC Sells 330 Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART)

Elkfork Partners LLC decreased its holdings in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 3.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,604 shares of the life sciences company’s stock after selling 330 shares during the period. Elkfork Partners LLC’s holdings in Integra Lifesciences were worth $592,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in IART. Clearbridge Investments LLC raised its holdings in Integra Lifesciences by 21.2% during the first quarter. Clearbridge Investments LLC now owns 2,442,164 shares of the life sciences company’s stock worth $136,077,000 after buying an additional 426,578 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Integra Lifesciences by 13.1% in the 2nd quarter. Janus Henderson Group PLC now owns 3,248,870 shares of the life sciences company’s stock worth $181,449,000 after acquiring an additional 375,546 shares in the last quarter. Fort Washington Investment Advisors Inc. OH bought a new stake in shares of Integra Lifesciences in the 1st quarter worth $14,145,000. Vaughan Nelson Investment Management L.P. grew its stake in shares of Integra Lifesciences by 26.1% in the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 1,110,177 shares of the life sciences company’s stock worth $61,860,000 after acquiring an additional 230,010 shares in the last quarter. Finally, First Trust Advisors LP grew its stake in shares of Integra Lifesciences by 922.1% in the 2nd quarter. First Trust Advisors LP now owns 211,299 shares of the life sciences company’s stock worth $11,801,000 after acquiring an additional 190,626 shares in the last quarter. Hedge funds and other institutional investors own 81.83% of the company’s stock.

Several equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Integra Lifesciences from a “hold” rating to a “buy” rating and set a $65.00 price target for the company in a research report on Monday, September 2nd. BidaskClub lowered shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 28th. JMP Securities increased their price target on shares of Integra Lifesciences to $75.00 in a research report on Thursday, July 25th. ValuEngine lowered shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a research report on Thursday, August 1st. Finally, Royal Bank of Canada set a $66.00 target price on shares of Integra Lifesciences and gave the stock a “hold” rating in a research report on Friday, July 26th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $62.67.

In other news, COO Glenn Coleman sold 3,500 shares of the firm’s stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $57.50, for a total value of $201,250.00. Following the transaction, the chief operating officer now owns 35,194 shares in the company, valued at $2,023,655. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Kenneth Burhop sold 6,656 shares of the firm’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $63.98, for a total transaction of $425,850.88. Following the completion of the transaction, the vice president now owns 15,921 shares in the company, valued at approximately $1,018,625.58. The disclosure for this sale can be found here. Insiders have sold 887,921 shares of company stock worth $54,121,075 over the last quarter. Company insiders own 4.50% of the company’s stock.

Shares of IART opened at $59.33 on Friday. The firm’s 50 day simple moving average is $60.88 and its 200 day simple moving average is $55.50. The company has a market capitalization of $5.22 billion, a P/E ratio of 23.28, a P/E/G ratio of 1.89 and a beta of 1.10. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.76 and a quick ratio of 1.82. Integra Lifesciences Holdings Corp has a 1-year low of $42.14 and a 1-year high of $66.41.

Integra Lifesciences (NASDAQ:IART) last announced its earnings results on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.08. Integra Lifesciences had a net margin of 6.76% and a return on equity of 16.30%. The business had revenue of $383.60 million for the quarter, compared to the consensus estimate of $373.29 million. During the same period last year, the firm posted $0.60 earnings per share. Integra Lifesciences’s quarterly revenue was up 4.8% on a year-over-year basis. On average, equities analysts anticipate that Integra Lifesciences Holdings Corp will post 2.73 earnings per share for the current year.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Recommended Story: Risk Tolerance and Your Investment Decisions

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply